Roche’s cobas EGFR Mutation Test for personalized treatment of non-small cell lung cancer receives CE mark
1 December 2011 | By Roche
Roche have announced that the cobas EGFR Mutation Test is now CE marked...
List view / Grid view
1 December 2011 | By Roche
Roche have announced that the cobas EGFR Mutation Test is now CE marked...
30 November 2011 | By Roche
Results from studies to be presented at SABCS...
18 November 2011 | By Roche
FDA Commissioner revokes approval of Avastin for treatment of mBC in the US...
9 November 2011 | By Roche
The vismodegib application has been granted priority review...
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
17 October 2011 | By Roche
Acquisition aims to expand future treatment options for hepatitis C patients...
17 October 2011 | By Roche
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin...
10 October 2011 | By Roche
Monoclonal antibody gantenerumab removes amyloid plaques from the brain...
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
8 September 2011 | By Roche
Roche recognized as the most sustainable healthcare company globally in the DJSI...
6 September 2011 | By Evotec AG
Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD) to be developed...
In this Genomics / Sequencing supplement: NGS powers up drug discovery and healthcare; Impact of novel sequencing technology on transcriptome analysis; Making sense of nonesense (and missense): Bringing the results of recent genetic studies into the drug discovery laboratory...
17 August 2011 | By Roche
First and only personalized medicine shown to help people with BRAF V600E mutation-positive metastatic melanoma...
4 August 2011 | By Roche
Lebrikizumab has potential to be the first personalized treatment for asthma...